Keyword: Verzenio (abemaciclib)
Lilly Oncology’s marketing chief has some key words for pharma marketers: Don’t lead with data. Put patients’ insights at the forefront instead.
Eli Lilly's oncology president Sue Mahony plans to retire at the end of August after 18 years with the drugmaker.
Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
It’s been only five months since Lilly breast cancer drug Verzenio launched, but it just racked up its third approval in a competitive market.
Trailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost.
With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
Lilly's new cancer drug Verzenio faces two tough rivals—Pfizer's Ibrance and Novartis' Kisquali—but the company says it's standing out from the crowd.
Eli Lilly’s Verzenio needs to stand out in a crowd, and now it's less likely that a lung cancer approval could be the solution.
Novartis wants to see some selfies. The company has recruited celebrity firepower for a social media push centered on metastatic breast cancer.
Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.